MedTrace Logo

Lorazepam, Diphenhydramine Hydrochloride, and Haloperidol Gel in Healthy Volunteers

NCT01204255 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2017-11-17

Study results available
· View outcomes & findings →

Summary

RATIONALE: Lorazepam, diphenhydramine hydrochloride, and haloperidol gel, when absorbed into the skin, may be an effective treatment for nausea and vomiting.PURPOSE: This clinical trial studies lorazepam, diphenhydramine hydrochloride, and haloperidol gel in healthy volunteers.

Conditions

  • Healthy

Interventions

DRUG

lorazepam

Given topically

DRUG

diphenhydramine hydrochloride

Given topically

DRUG

haloperidol

Given topically

OTHER

questionnaire administration

Ancillary studies

OTHER

laboratory biomarker analysis

Correlative studies

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • American Cancer Society, Inc.

    collaborator OTHER

  • Virginia Commonwealth University

    lead OTHER

Principal Investigators

  • Thomas Smith · Virginia Commonwealth University

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-11-15
Primary Completion
2011-04-18
Completion
2011-05-17

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01204255 on ClinicalTrials.gov